185 related articles for article (PubMed ID: 18376061)
1. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.
Carlsson CM; Gleason CE; Hess TM; Moreland KA; Blazel HM; Koscik RL; Schreiber NT; Johnson SC; Atwood CS; Puglielli L; Hermann BP; McBride PE; Stein JH; Sager MA; Asthana S
J Alzheimers Dis; 2008 Mar; 13(2):187-97. PubMed ID: 18376061
[TBL] [Abstract][Full Text] [Related]
2. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Riekse RG; Li G; Petrie EC; Leverenz JB; Vavrek D; Vuletic S; Albers JJ; Montine TJ; Lee VM; Lee M; Seubert P; Galasko D; Schellenberg GD; Hazzard WR; Peskind ER
J Alzheimers Dis; 2006 Dec; 10(4):399-406. PubMed ID: 17183151
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
4. Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.
Höglund K; Syversen S; Lewczuk P; Wallin A; Wiltfang J; Blennow K
Exp Brain Res; 2005 Jul; 164(2):205-14. PubMed ID: 15937702
[TBL] [Abstract][Full Text] [Related]
5. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
6. Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
Lodeiro M; Ibáñez C; Cifuentes A; Simó C; Cedazo-Mínguez Á
J Alzheimers Dis; 2014; 41(1):223-32. PubMed ID: 24595197
[TBL] [Abstract][Full Text] [Related]
7. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.
Simons M; Schwärzler F; Lütjohann D; von Bergmann K; Beyreuther K; Dichgans J; Wormstall H; Hartmann T; Schulz JB
Ann Neurol; 2002 Sep; 52(3):346-50. PubMed ID: 12205648
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
Sano M; Bell KL; Galasko D; Galvin JE; Thomas RG; van Dyck CH; Aisen PS
Neurology; 2011 Aug; 77(6):556-63. PubMed ID: 21795660
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
Li G; Mayer CL; Morelli D; Millard SP; Raskind WH; Petrie EC; Cherrier M; Fagan AM; Raskind MA; Peskind ER
Neurology; 2017 Sep; 89(12):1251-1255. PubMed ID: 28821686
[TBL] [Abstract][Full Text] [Related]
10. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
[TBL] [Abstract][Full Text] [Related]
11. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
12. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
13. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.
Kessler H; Pajonk FG; Bach D; Schneider-Axmann T; Falkai P; Herrmann W; Multhaup G; Wiltfang J; Schäfer S; Wirths O; Bayer TA
J Neural Transm (Vienna); 2008 Dec; 115(12):1651-9. PubMed ID: 18972062
[TBL] [Abstract][Full Text] [Related]
14. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.
Hoglund K; Thelen KM; Syversen S; Sjogren M; von Bergmann K; Wallin A; Vanmechelen E; Vanderstichele H; Lutjohann D; Blennow K
Dement Geriatr Cogn Disord; 2005; 19(5-6):256-65. PubMed ID: 15785028
[TBL] [Abstract][Full Text] [Related]
15. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
[TBL] [Abstract][Full Text] [Related]
16. Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Wei S; Dang L; Gao F; Wang J; Wang J; Qu Q
J Alzheimers Dis; 2022; 90(1):349-362. PubMed ID: 36120775
[TBL] [Abstract][Full Text] [Related]
17. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
[TBL] [Abstract][Full Text] [Related]
18. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.
Fassbender K; Simons M; Bergmann C; Stroick M; Lutjohann D; Keller P; Runz H; Kuhl S; Bertsch T; von Bergmann K; Hennerici M; Beyreuther K; Hartmann T
Proc Natl Acad Sci U S A; 2001 May; 98(10):5856-61. PubMed ID: 11296263
[TBL] [Abstract][Full Text] [Related]
20. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
